6,678 trials
Osteoporosis · Hypercholesterolemia
Primary: Relative Change in OPG/RANK/RANKL mRNA Expression in Isolated T Cells and Monocytes — 0.76 relative fold change — p=<0.05
Substance-Related Disorders
Primary: Change in Time Spent in Drug-paired Room — 24.5; 6.2 seconds
Irritable Bowel Syndrome With Diarrhea
Primary: Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period — 5.89; 5.34; -1.25; -1.09 score on a scale
Labor Pain
Primary: Change of Maximum Pain During Contraction at 20 Minutes After the Study Drug Delivery — 60; 36; 67; 42 mm
Cardiac Arrythmias
Primary: Tp-e — 69.5; 74.7 milliseconds
Hepatitis C, Chronic · Hepatitis C · Opiate Dependence
Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment (SVR-12) — 7 Participants
Tuberculosis
Primary: Step 1: Positive Detection Accuracy (PDA) — 99.3 percentage of DHFS detected doses
HIV Prevention · Transgender Health
Primary: Tenofovir Diphosphate Concentration in Dried Blood Spots (DBS) — 973.5; 1078 fmol/punch
Femoro Acetabular Impingement
Primary: Visual Analogue Scale — 2.4; 2.7 cm
Smoking Cessation · Smoking Behaviors · Smoking
Primary: Change in Self-Reported Craving Level Via Lab-Based Cue Reactivity — 6.31; 4.2; 2.56; 2.4 score on a scale
Renal Failure Chronic · Hepatitis C
Primary: Number of Participants With Undetectable HCV — 30 Participants
Surgical Site Infection
Primary: Culture Positivity — 14; 13; 63; 63 Participants
Psoriatic Arthritis
Primary: Number of Participants Who Are Eligible, Consent, and Complete the 48 Weeks Study — 0 Participants
Osteoarthritis, Hip
Primary: Percentage Ambulating Early After Spinal Anesthesia — 9; 20; 35 Participants
Hypercholesterolemia
Primary: Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96 — -0.180…